Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Poster Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients CertaraApril 22, 2019
Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Poster Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies CertaraApril 22, 2019
Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Poster Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation CertaraApril 22, 2019
Real World Evidence Marches Forward in Drug Development Blog Real World Evidence Marches Forward in Drug Development The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…CertaraMarch 20, 2019
How to Perform IVIVC for Extremely Long Acting Drugs On-Demand Webinar How to Perform IVIVC for Extremely Long Acting Drugs Watch this webinar to learn how to use in vitro and in vivo models to…CertaraFebruary 22, 2019
Managing Immunogenicity Using Quantitative Systems Pharmacology Blog Managing Immunogenicity Using Quantitative Systems Pharmacology The Challenge of Immunogenicity in Biologics Drug Development Biologic drug development is a rapidly evolving…CertaraFebruary 22, 2019
PBPK’s Pivotal Role in Modern Drug Development: Busting Common Myths and Misconceptions White Paper PBPK’s Pivotal Role in Modern Drug Development: Busting Common Myths and Misconceptions This white paper addresses common PBPK myths and misconceptions and demonstrates how this approach is…CertaraFebruary 4, 2019
Automated Average Bioequivalence Analysis with Additional Metrics and Statistics to Meet the FDA Guidance on Methylphenidate Hydrochloride Using Phoenix WinNonlin Poster Automated Average Bioequivalence Analysis with Additional Metrics and Statistics to Meet the FDA Guidance on Methylphenidate Hydrochloride Using Phoenix WinNonlin CertaraNovember 4, 2018
7 Things to Know About the China Pharmaceutical Industry Blog 7 Things to Know About the China Pharmaceutical Industry China is the second largest pharmaceutical market in the world. Demand is likely to increase…CertaraOctober 16, 2018
Development of a Pre-clinical Quantitative Systems Pharmacology Model for E7046, a Novel PGE2 Receptor Type 4 Antagonist for Cancer Immunotherapy Poster Development of a Pre-clinical Quantitative Systems Pharmacology Model for E7046, a Novel PGE2 Receptor Type 4 Antagonist for Cancer Immunotherapy CertaraOctober 8, 2018